Independent review of AGO-OVAR 12, a GCIG/ENGOT-Intergroup phase III trial of nintedanib (N) in first-line therapy for ovarian cancer (OC)

Autor:	Sandro Pignata, Philipp Harter, Petronella B. Ottevanger, Alexander Reinthaller, Martin Oliver Sailer, Susanne Malander, Nikolaus de Gregorio, Nicoletta Colombo, Frédéric Goffin, Mansoor Raza Mirza, Florence Joly, Margarita Romeo, Jacobus Pfisterer, Olivier Tredan, Aristotelis Bamias, Michael Merger, Andreas du Bois, Tomas Minarik, Gunnar B. Kristensen, Rainer Kimmig
Rok vydání:	2014
Předmět:	Oncology Cancer Research Chemotherapy medicine.medical_specialty biology business.industry medicine.medical_treatment VEGF receptors Medizin Placebo medicine.disease Surgery chemistry.chemical_compound First line therapy chemistry Internal medicine embryonic structures cardiovascular system biology.protein Medicine Nintedanib biological phenomena cell phenomena and immunity business Ovarian cancer
Zdroj:	Journal of Clinical Oncology. 32:5556-5556
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2014.32.15_suppl.5556
Popis:	5556^ Background: N is an oral inhibitor of VEGFR, PDGFR, and FGFR. As reported earlier, in the AGO-OVAR12 trial, N compared to placebo (Pl), added to standard chemotherapy, significantly prolonged...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cec798c3d1c06771883121d5af9d8336 https://doi.org/10.1200/jco.2014.32.15_suppl.5556 Zobrazit plný text záznamu